Drug Trial Radar · NCT05085977
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Mar 10, 2022
Primary completion
Sep 3, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- Protara TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label dose escalation study (Phase 1a) to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of bladder tumor (TURBT) and/or biopsy using TARA-002 in adults unable to obtain intravesical Bacillus Calmette-Guérin (BCG), adults who have received at least one dose of intravesical BCG or adults who have received at least one dose of intravesical chemotherapy. Dosing will start in subjects with HGTa or CIS (including CIS with concomitant Ta), and all subjects will receive 6 weeks of treatment at a fixed volume with varying dose levels.
Conditions
- Non-muscle Invasive Bladder Cancer
Interventions
TARA-002Biological
Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a, Dose Escalation Phase: Incidence of DLT AEs in subjects with HGTa or CIS NMIBCTime frame: Day 1 to Day 43
- Phase 1a, Dose Escalation Phase: MTD and RP2D of TARA-002 in subjects with HGTa or CIS NMIBCTime frame: Day 1 to Day 43
Locations
14 sites in 4 countries. Site status is shown where the registry gives one.
USC Norris Cancer Center
Los Angeles, California
Mayo Clinic
Jacksonville, Florida
Tulane Medical Center
New Orleans, Louisiana
Chesapeake Urology Research Associates
Baltimore, Maryland
Mayo Clinic
Rochester, Minnesota
New Jersey Urology
Mount Laurel, New Jersey
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York
University of Rochester, Department of Urology
Rochester, New York
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Urology Associates PC
Nashville, Tennessee
UT Health San Antonio
San Antonio, Texas
PMSI Republican Clinical Hospital "T. Mosneaga," ARENSIA Exploratory Medicine Phase I Unit
Chisinau, Moldova
Spitalul Clinic de Nefrologie Carol Davila
Bucharest, Romania
Arensia Kapitanivka
Kapitanivka, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.